Demetrix is a biotechnology company that believes in the power of science to make the world a better place. The company produces effective health and wellness products backed by science, including rare, high-purity cannabinoids for pharmaceutical and consumer applications.
Demetrix has a team of industry-leading experts across R&D, production, regulation, and commercialization, with deep experience bringing fermentation products to market. The company is pioneering the study of the more than 100 rare cannabinoids and their interactions with the human body.
Demetrix has raised $61 million in venture funding and is based in Berkeley, California.
Demetrix has a team of industry-leading experts across R&D, production, regulation, and commercialization, with deep experience bringing fermentation products to market. The company is pioneering the study of the more than 100 rare cannabinoids and their interactions with the human body.
Demetrix has raised $61 million in venture funding and is based in Berkeley, California.
Location: Australia, New South Wales, Berkeley
Employees: 51-200
Total raised: $50M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Berkeley C... | berkeleyca... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.07.2019 | Series A | $50M | - |
Mentions in press and media 6
| Date | Title | Description |
| 15.04.2021 | Why Synthetic Cannabinoids Can Be a Good Thing | April 15, 2021 4 min read Opinions expressed by Entrepreneur contributors are their own. The use of synthetic cannabinoids is a controversial issue in the cannabis industry. It could be an opportunity to advance the research and development... |
| 11.07.2019 | Demetrix raises $50 million to brew cannabis | With skyrocketing demand for consumer products and renewed research into its medicinal value, cannabis is having a moment. The quasi-legalization of marijuana created a gold rush for the industry, and startups like Demetrix are reaping the ... |
| 11.07.2019 | Cannabis processing startups hope to unlock new chemicals and treatments | Jeff Ubersax knows yeast. The chief executive officer of Demetrix studied yeast genetics and biochemistry in school and was an early employee at Amyris Biotechnologies, a technology company that was using fermentation to make biofuels back ... |
| 11.07.2019 | Demetrix Raises $50M In Series A Funding | Demetrix Inc., an Emeryville, Calif.-based biotechnology company focused on the production of cannabinoids, secured $50m in Series A funding. The round was led by Tuatara Capital with participation from existing investor Horizons Ventures. ... |
| 06.04.2019 | 'Think of yeast as a factory...' Microbial fermentation can deliver CBD with consistent purity at a lower cost, says Demetrix | It also uses less land, water and energy, and enables firms to produce rarer cannabinoids it would not be commercially viable to extract from plants, Jeff Ubersax, PhD, CEO at Emeryville-CA-based Demetrix told FoodNavigator-USA. “There is... |
| 20.03.2019 | Amyris teams up with LAVVAN to bring fermentation-derived CBD to market in 2020: 'There's a significant cost advantage' | The news follows a string of announcements from firms also developing platforms to biosynthesize cannabinoids via fermentation including Demetrix, Librede; InMed Pharmaceuticals; Hyasynth, which is working with Organingram; Gingk... |